Form 8-K - Current report:
SEC Accession No. 0001493152-24-028157
Filing Date
2024-07-17
Accepted
2024-07-17 15:50:36
Documents
16
Period of Report
2024-07-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 53490
2 ex4-1.htm EX-4.1 67839
3 ex10-1.htm EX-10.1 12442
  Complete submission text file 0001493152-24-028157.txt   320073

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE pvct-20240711.xsd EX-101.SCH 3027
5 XBRL LABEL FILE pvct-20240711_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE pvct-20240711_pre.xml EX-101.PRE 22367
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3367
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36457 | Film No.: 241122113
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)